Clinical trials: Prognostic Cancer Model
Lung Adenocarcinoma, Surgery
DNA Methylation Biomarkers to Predict Survival After Surgery for Lung Adenocarcinoma
This study is designed to assess DNA 5-methylcytosine (5mC) methylation modifications in lung adenocarcinoma (LUAD) samples and develop a prognosis-predictive model for LUAD based on cancer tissue DNA 5mC levels.
- Conditions
- Lung Adenocarcinoma, Surgery, Prognostic Cancer Model
- Trial name
- NCT06477211
- Where
- China
- Volunteers
- 292 people
- Sponsor
- Nanjing University
Prostate Cancer Metastatic
Expression of Molecular Markers in Circulating Tumor Cells of Metastatic Castration-Resistant Prostate Cancer
As prostate cancer progresses into castration-resistant stage from initial hormone-sensitive status, the biological behavior of tumor cells that dissociated from primary lesions changed.
- Trial name
- NCT03089099
- Testing
- Blood drawing
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Fudan University
Endometrium Cancer
Stratifying Endometrial Cancer Patients Using a PET/MRI Prognostic Model
Endometrial cancer (EC) is the most common gynecological malignancy in high-income countries. Prognosis and treatment are dictated by cancer histological subtype and grade coupled with surgical staging as described by Surgical…
- Trial name
- NCT04212910
- Where
- Italy
- Volunteers
- 86 people
- Sponsor
- IRCCS San Raffaele
Prostate Cancer
Expression of Tumor Markers in Circulating Tumor Cells of Metastatic Hormone-sensitive Prostate Cancer
As prostate cancer progresses, tumor cells dissociate and enter the bloodstream. Considered a "liquid biopsy," these circulating tumor cells (CTC) can show how a patient's cancer evolves and responds to treatments.
- Trial name
- NCT02723526
- Testing
- Blood drawing
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Fudan University
Gliomas Harboring IDH1 and/or IDH2 Mutations, Glioma Glioblastoma Multiforme
Multicenter Prospective Study on MRI AI Model for Midline Glioma Subtyping and Prognosis:
A vision-language model using preoperative MRI and clinical variables has been developed to simultaneously predict three key molecular markers in midline gliomas: H3K27M, IDH, and 1p/19q.
- Conditions
- Gliomas Harboring IDH1 and/or IDH2 Mutations, Glioma Glioblastoma Multiforme, Glioma of Brainstem, Glioma, Diffuse Midline, H3K27M-mutant
- Trial name
- NCT07608003
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Xiangya Hospital of Central South University
HCC - Hepatocellular Carcinoma
Sarcopenia and Systemic Therapy in HCC
This is a multi-center, retrospective observational study in patients with liver cancer (HCC) to assess the impact of sarcopenia (muscle loss) on the prognosis, duration, and tolerance of systemic treatment.
- Trial name
- Sarco HCC (NCT06805552)
- Where
- Italy
- Volunteers
- 270 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Hodgkin Disease, Lymphoma, Non-Hodgkin
Tissue Collection for Studies of Lymph Cancer
Background: Lab studies help researchers better understand cancer biology. This information may lead to new methods for diagnosing or treating cancer.
- Conditions
- Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Lymphomatoid Granulomatosis
- Trial name
- NCT01676805
- Where
- 2 sites in United States, Jamaica
- Volunteers
- 1,295 people
- Sponsor
- National Cancer Institute (NCI)
Phyllodes Breast Tumor, Artificial Intelligence
AI-Assisted System for Accurate Diagnosis and Prognosis of Breast Phyllodes Tumors
Breast phyllodes tumor (PT) is a rare fibroepithelial tumor, accounting for 1% to 3% of all breast tumors, categorized by the WHO into benign, borderline, and malignant, based on histopathology features such as tumor border…
- Conditions
- Phyllodes Breast Tumor, Artificial Intelligence, Multiomics, Prognostic Cancer Model
- Trial name
- NCT06286267
- Testing
- imaging
- Where
- 4 sites in China
- Volunteers
- 4,000 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Cancer, Predictive Cancer Model
KM3D Multicenter Cancer Consortium: Predicting Patient Response Using 3D Cell Culture Models
This study will assess the ability of the Known Medicine platform to predict the efficacy of certain cancer drug treatments and to validate that tumor organoid drug sensitivity is representative of patient treatment outcomes.
- Conditions
- Cancer, Predictive Cancer Model, Effects of Chemotherapy
- Trial name
- NCT05338073
- Testing
- Known 3Dx Test
- Where
- 3 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- Known Medicine, Inc.
Colorectal Cancer, Polyps
The Correlation of Postoperative Polyp Recurrence and Colorectal Cancer
Postoperative endoscopic polyp recurrence correlation of colorectal cancer: a retrospective cohort open-label study
- Trial name
- NCT07708415
- Testing
- Endoscopic polypectomy
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- Gansu Provincial Hospital
Glioma
The Predictive Value of MRI for Adult-type Diffuse Gliomas
The goal of this observational study is to learn about the diagnostic value of preoperative MRI examination for adult-type diffuse gliomas.
- Trial name
- MRI; glioma; (NCT06572592)
- Volunteers
- 200 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Colorectal Cancer, Colorectal Adenoma
COLO-COHORT (Colorectal Cancer Cohort) Study
This is a cross-sectional study aimed at identifying factors which best predicts patients at high risk of colorectal cancer or colorectal adenomas and to develop a risk prediction model.
- Conditions
- Colorectal Cancer, Colorectal Adenoma, Colorectal Neoplasm, Predictive Cancer Model
- Trial name
- NCT04185779
- Testing
- Colonoscopy
- Where
- 3 sites in United Kingdom
- Volunteers
- 15,000 people
- Sponsor
- South Tyneside and Sunderland NHS Foundation Trust
Pancreatic Adenocarcinoma, Predictive Cancer Model
Prospective Validation of an EHR-based Pancreatic Cancer Risk Model
The goal of this prospective observational cohort study is to validate a previously developed pancreatic cancer risk prediction algorith (the PRISM model) using electronic health records from the general population.
- Trial name
- NCT05973331
- Testing
- Pancreatic Cancer Risk Model (PRISM)
- Where
- United States
- Volunteers
- 6,134,060 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
Gastric Cancer (GC)
Development and Validation of the Surgical Assessment and Healthcare (SAH) Index for Gastric Cancer Treatment Evaluation
This study develops the Surgical Assessment and Healthcare (SAH) Index, a new tool to fairly evaluate gastric cancer surgery outcomes.
- Trial name
- SAH (NCT07180966)
- Where
- China
- Volunteers
- 780 people
- Sponsor
- Ruijin Hospital
Biliary Tract Cancer, Immune Checkpoint Inhibitor
Exploratory Study on the Therapeutic Effect Prediction Model of Advanced BTC Immunotherapy
1. Establish a predictive model for the efficacy of immune checkpoint inhibitors (ICI) in Chinese patients with biliary tract cancers.
- Conditions
- Biliary Tract Cancer, Immune Checkpoint Inhibitor, Predictive Cancer Model
- Trial name
- NCT06074029
- Testing
- Immune Checkpoint Inhibitors
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking Union Medical College Hospital
Oncology, Bladder Cancer
A New Prognostic Model for Predicting the Outcome of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)
A prospective observational study to re-establish a new prognostic model for predicting the outcome in patients with non-muscle invasive bladder cancer (NMIBC) using the current recommendation regimen for intermediate and high…
- Conditions
- Oncology, Bladder Cancer, Superficial Bladder Cancer, Recurrence
- Trial name
- NCT03121768
- Where
- Egypt
- Volunteers
- 761 people
- Sponsor
- Mansoura University
Gastric Cancer
Hematological Dynamic Scores for Predicting Survival and Treatment Response for Advanced Gastric Cancer After Neoadjuvant Therapy
HMDLS, based on hematological markers, could effectively distinguish the long-term efficacy of AGC patients after NAT. The predictive performance of nomogram-HMDLS was better than ypTNM stage, achieving better prognostic…
- Trial name
- NCT06573307
- Where
- China
- Volunteers
- 442 people
- Sponsor
- Chang-Ming Huang, Prof.
Solid Tumor, Predictive Cancer Model
Radiomics of Immunotherapeutics Response Evaluation and Prediction
This study aims to investigate the feasibility and efficiency of CT radiomic analysis which serves as a high through-put analytical strategy applied to image big-data resource in evaluating and predicting the response of…
- Trial name
- RIREP (NCT04079283)
- Testing
- Clinical, Semantic, Radiomic
- Where
- China
- Volunteers
- 285 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Pseudomyxoma Peritonei, Colorectal Carcinoma
Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies
The aim of this study is to identify biomarkers of disease recurrence and prognosis to optimize patient selection for treatment with cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC), and through…
- Conditions
- Pseudomyxoma Peritonei, Colorectal Carcinoma, Ovarian Carcinoma, Mesothelioma
- Trial name
- PSM (NCT02073500)
- Testing
- Observational study.
- Where
- Norway
- Volunteers
- 300 people
- Sponsor
- Oslo University Hospital
Hodgkin Lymphoma
Prognostic Model of Elderly Hodgkin Lymphoma in China
This multicenter observational cohort study is based on a patient registry designed to systematically collect uniform real-world clinical data from elderly patients with Hodgkin lymphoma (HL) in China.
- Trial name
- NCT07374068
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital